| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT04179019 |
| P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
| P582 | end time | 2025-03-30 | |
| P4135 | maximum age | 80 | |
| P1050 | medical condition | hyperplasia | Q835051 |
| hyperaldosteronism | Q1640860 | ||
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 15 | |
| P4844 | research intervention | calcium oxalate | Q412399 |
| P1813 | short name | CCB-PA | |
| P859 | sponsor | Brigham and Women's Hospital | Q2900977 |
| P580 | start time | 2020-04-01 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | Calcium Channel Blockade in Primary Aldosteronism |